Skip to main content
SpringerLink
Log in

Chemoprevention of Breast Cancer

  • Chapter
Management of Breast Diseases

  • 1899 Accesses

Abstract

Breast cancer is the most common cancer affecting women worldwide. Approximately 210,000 new cases are reported annually in the United States, and there are about 1.2 million incident cases [1]. Globally, the incidence is rising rapidly, coincident with rising socioeconomic development, as exemplified in Southeast Asia. Early detection and treatment of breast cancer have resulted in an important but modest reduction in mortality [2]. Furthermore, despite data implicating diet and other environmental risk factors discussed in this and other chapters, no specific lifestyle changes have yet been shown to significantly reduce the risk of breast cancer. It is thus logical to explore chemoprevention as a way to address this urgent public health issue.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, Thun MJ, Ries LA et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 100(23):1672–94

    PubMed  Google Scholar 

  2. Chu KC, Tarone RE, Kessler LG et al (1996) Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst. 88(21):1571–9

    CAS  PubMed  Google Scholar 

  3. Hulka BS, Liu ET, Lininger RA (1994) Steroid hormones and risk of breast cancer. Cancer. 74(3 Suppl):1111–24

    CAS  PubMed  Google Scholar 

  4. Brzozowski AM, Pike AC, Dauter Z et al (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389(6652):753–8

    CAS  PubMed  Google Scholar 

  5. Santen RJ, Yue W, Naftolin F, Mor G, Berstein L (1999) The potential of aromatase inhibitors in breast cancer prevention. Endocr Relat Cancer. 6(2):235–43

    CAS  PubMed  Google Scholar 

  6. Bugano DD, Conforti-Froes N, Yamaguchi NH, Baracat EC (2008) Genetic polymorphisms, the metabolism of estrogens and breast cancer: a review. Eur J Gynaecol Oncol. 29(4):313–20

    CAS  PubMed  Google Scholar 

  7. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE (2008) Circulating 2-hydroxy-and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomark Prev. 17(8):2029–35

    CAS  Google Scholar 

  8. Justenhoven C, Hamann U, Pierl CB et al (2008) CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 115(2):391–6

    PubMed  Google Scholar 

  9. Ahlgren M, Melbye M, Wohlfahrt J, Sorensen TI (2004) Growth patterns and the risk of breast cancer in women. N Engl J Med. 351(16):1619–26

    CAS  PubMed  Google Scholar 

  10. Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol. 36:203–32

    CAS  PubMed  Google Scholar 

  11. Boyd NF, Byng JW, Jong RA et al (1995) Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 87(9):670–5

    CAS  PubMed  Google Scholar 

  12. Zhang Y, Kiel DP, Kreger BE et al (1997) Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med. 336(9):611–7

    CAS  PubMed  Google Scholar 

  13. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A et al (1995) A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst. 87(3):190–7

    CAS  PubMed  Google Scholar 

  14. Byrne C, Schairer C, Wolfe J et al (1995) Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst. 87(21):1622–9

    CAS  PubMed  Google Scholar 

  15. Goss PE, Sierra S (1998) Current perspectives on radiation-induced breast cancer. J Clin Oncol. 16(1):338–47

    CAS  PubMed  Google Scholar 

  16. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283(4): 485–91

    CAS  PubMed  Google Scholar 

  17. Adami HO, Signorello LB, Trichopoulos D (1998) Toward an understanding of breast cancer etiology. Semin Cancer Biol. 8(4):255–62

    CAS  PubMed  Google Scholar 

  18. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR (1996) Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of osteoporotic fractures research group. JAMA. 276(17):1404–8

    CAS  PubMed  Google Scholar 

  19. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR (1999) Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 130(4 Pt 1):270–7

    CAS  PubMed  Google Scholar 

  20. Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasa S (1990) Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer. 46(5):796–800

    CAS  PubMed  Google Scholar 

  21. Easton D, Ford D, Peto J (1993) Inherited susceptibility to breast cancer. Cancer Surv. 18:95–113

    CAS  PubMed  Google Scholar 

  22. Anon. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350(9084):1047–59

    Google Scholar 

  23. Colditz GA, Hankinson SE, Hunter DJ et al (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332(24):1589–93

    CAS  PubMed  Google Scholar 

  24. Gail MH, Costantino JP, Pee D et al (2007) Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 99(23):1782–92

    PubMed  Google Scholar 

  25. Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 81(24):1879–86

    CAS  PubMed  Google Scholar 

  26. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 90(18):1371–88

    CAS  PubMed  Google Scholar 

  27. Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 295(23):2727–41

    CAS  PubMed  Google Scholar 

  28. Clarke R (1996) Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat. 39(1):69–86

    CAS  PubMed  Google Scholar 

  29. Banks WA (2006) The blood-brain barrier in psychoneuroimmunology. Neurol Clin. 24(3):413–9

    PubMed  Google Scholar 

  30. Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A (1999) The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat. 57(2):183–92

    CAS  PubMed  Google Scholar 

  31. Russo J, Russo IH (1996) Experimentally induced mammary tumors in rats. Breast Cancer Res Treat. 39(1):7–20

    CAS  PubMed  Google Scholar 

  32. Fisher B, Costantino J, Redmond C et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med. 320(8):479–84

    Article  CAS  PubMed  Google Scholar 

  33. Rutqvist LE, Cedermark B, Glas U et al (1991) Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst. 83(18):1299–306

    CAS  PubMed  Google Scholar 

  34. Anon. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Report from the breast cancer trials committee, Scottish cancer trials office (MRC), Edinburgh. Lancet. 1987;2(8552):171–5

    Google Scholar 

  35. Fisher B, Redmond C (1991) New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst. 83(18):1278–80

    CAS  PubMed  Google Scholar 

  36. Anon. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early breast cancer trialists’ Collaborative Group. Lancet. 1992;339(8785):71–85

    Google Scholar 

  37. Anon. Tamoxifen for early breast cancer: an overview of the randomized trials. Early breast cancer trialists’ Collaborative Group. Lancet. 1998;351(9114):1451–67

    Google Scholar 

  38. Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Italian Tamoxifen Prevention Study. Lancet. 352(9122):93–7

    CAS  PubMed  Google Scholar 

  39. Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 352(9122):98–101

    CAS  PubMed  Google Scholar 

  40. Cuzick J, Forbes JF, Sestak I et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 99(4):272–82

    CAS  PubMed  Google Scholar 

  41. McDonald CC, Stewart HJ (1991) Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish breast cancer committee. BMJ. 303(6800):435–7

    CAS  PubMed  Google Scholar 

  42. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J (1997) Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst. 89(11):776–82

    CAS  PubMed  Google Scholar 

  43. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ (1995) Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. The Scottish cancer trials breast group. BMJ. 311(7011):977–80

    CAS  PubMed  Google Scholar 

  44. Rutqvist LE, Mattsson A (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 85(17):1398–406

    CAS  PubMed  Google Scholar 

  45. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ (1994) Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med. 154(22):2585–8

    CAS  PubMed  Google Scholar 

  46. Love RR, Mazess RB, Barden HS et al (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 326(13):852–6

    Article  CAS  PubMed  Google Scholar 

  47. Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC (1988) Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat. 12(3):297–302

    CAS  PubMed  Google Scholar 

  48. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG (1999) American society of clinical oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol. 17(6):1939–55

    CAS  PubMed  Google Scholar 

  49. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B (1999) Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast And Bowel Project P-1 Study. J Clin Oncol. 17(9):2659–69

    CAS  PubMed  Google Scholar 

  50. Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA. 281(23):2189–97

    CAS  PubMed  Google Scholar 

  51. Jordan VC, Glusman JE, Eckert S. Raloxifene reduces incident primary breast cancer: integrated data from multicenter, double-blind, place bo-controlled, randomized trials in postmenopausal women. Breast Cancer Res Treat. 1998;50(3): 227. Ref Type: abstr

    Google Scholar 

  52. Delmas PD, Bjarnason NH, Mitlak BH et al (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 337(23):1641–7

    CAS  PubMed  Google Scholar 

  53. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW (1997) Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 177(6):1458–64

    CAS  PubMed  Google Scholar 

  54. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA. 282(7):637–45

    CAS  PubMed  Google Scholar 

  55. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C (1996) A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 11(6): 835–42

    CAS  PubMed  Google Scholar 

  56. Walsh BW, Kuller LH, Wild RA et al (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 279(18):1445–51

    CAS  PubMed  Google Scholar 

  57. Glusman JE, Lu Y, Huster WJ. Raloxifene effects on climacteral symptoms compared with hormone or estrogen replacement therapy (HRT or ERT). Proc North Am Menopause Soc 8th Annual Meeting Program. 1997. Ref Type: abstr

    Google Scholar 

  58. Buzdar AU, Hortobagyi G (1998) Update on endocrine therapy for breast cancer. Clin Cancer Res. 4(3):527–34

    CAS  PubMed  Google Scholar 

  59. Hayes DF, Van Zyl JA, Hacking A et al (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 13(10):2556–66

    CAS  PubMed  Google Scholar 

  60. Holli K (1997) Evolving role of toremifene in the adjuvant setting. Oncology (Williston Park). 11(5 Suppl 4):48–51

    CAS  Google Scholar 

  61. Holli K (1998) Adjuvant trials of toremifene vs tamoxifen: the European experience. Oncology (Williston Park). 12(3 Suppl 5):23–7

    CAS  Google Scholar 

  62. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I (1996) Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol. 14(2):429–33

    CAS  PubMed  Google Scholar 

  63. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O (1998) Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab. 83(4):1158–62

    CAS  PubMed  Google Scholar 

  64. Bruning PF (1992) Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer. 28A(8–9):1404–7

    CAS  PubMed  Google Scholar 

  65. Haarstad H, Lonning PE, Gundersen S, Wist E, Raabe N, Kvinnsland S (1998) Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment. Acta Oncol. 37(4):365–8

    CAS  PubMed  Google Scholar 

  66. Simard J, Labrie C, Belanger A et al (1997) Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int J Cancer. 73(1):104–12

    CAS  PubMed  Google Scholar 

  67. Simard J, Sanchez R, Poirier D et al (1997) Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res. 57(16):3494–7

    CAS  PubMed  Google Scholar 

  68. Labrie F, Labrie C, Belanger A et al (1999) EM-652 (SCH 57068), a third-generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol. 69(1–6):51–84

    CAS  PubMed  Google Scholar 

  69. Luo S, Sourla A, Labrie C et al (1998) Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogensensitive parameters in intact and ovariectomized mice. Endocrinology. 139(5):2645–56

    CAS  PubMed  Google Scholar 

  70. Tremblay A, Tremblay GB, Labrie C, Labrie F, Giguere V (1998) EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta. Endocrinology. 139(1):111–8

    CAS  PubMed  Google Scholar 

  71. Rosati RL, Da Silva JP, Cameron KO et al (1998) Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem. 41(16): 2928–31

    CAS  PubMed  Google Scholar 

  72. Ke HZ, Paralkar VM, Grasser WA et al (1998) Effects of CP-336, 156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology. 139(4):2068–76

    CAS  PubMed  Google Scholar 

  73. Curiel MD, Calero JA, Guerrero R, Gala J, Gazapo R, de la Piedra C (1998) Effects of LY-117018 HCl on bone remodeling and mineral density in the oophorectomized rat. Am J Obstet Gynecol. 178(2):320–5

    CAS  PubMed  Google Scholar 

  74. Hodsman AB, Drost D, Fraher LJ et al (1999) The addition of a raloxifene analog (LY117018) allows for reduced PTH(1–34) dosing during reversal of osteopenia in ovariectomized rats. J Bone Miner Res. 14(5):675–9

    CAS  PubMed  Google Scholar 

  75. LaCroix AZ, Cummings SR, Thompson DJ, et al. Effects of 5 years of treatment with lasofoxifene on the incidence of breast cancer in older women. Breast Cancer Res Treat. 69(2suppl). 2008. Ref Type: abstr

    Google Scholar 

  76. Howell A, DeFriend DJ, Robertson JF et al (1996) Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer. 74(2):300–8

    CAS  PubMed  Google Scholar 

  77. Howell A, DeFriend D, Robertson J, Blamey R, Walton P (1995) Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 345(8941): 29–30

    CAS  PubMed  Google Scholar 

  78. Nicholson RI, Gee JM, Manning DL, Wakeling AE, Montano MM, Katzenellenbogen BS (1995) Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and-resistant experimental and clinical breast cancer. Ann N Y Acad Sci. 761:148–63

    CAS  PubMed  Google Scholar 

  79. Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ (1994) Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis. 15(12):2775–80

    CAS  PubMed  Google Scholar 

  80. De Coster R, Van Ginckel RF, Callens MJ, Goeminne NK, Janssens BL (1992) Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors. Cancer Res. 52(5):1240–4

    PubMed  Google Scholar 

  81. Bhatnagar AS, Hausler A, Schieweck K, Lang M, Bowman R (1990) Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 37(6):1021–7

    CAS  PubMed  Google Scholar 

  82. Schieweck K, Bhatnagar AS, Batzl C, Lang M (1993) Antitumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol. 44(4–6):633–6

    CAS  PubMed  Google Scholar 

  83. Goss PE, Winer EP, Tannock IF, Schwartz LH (1999) Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol. 17(1):52–63

    CAS  PubMed  Google Scholar 

  84. Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer. 98(9):1802–10

    CAS  PubMed  Google Scholar 

  85. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 350(11):1081–92

    CAS  PubMed  Google Scholar 

  86. Thuerlimann B, Keshaviah A, Mouridsen H, et al BIG 1–98: randomized, double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Proc Am Soc Clin Oncol. 24, No. 511. 2005. Ref Type: abstr

    Google Scholar 

  87. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG et al (1995) Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 87(10):746–50

    CAS  PubMed  Google Scholar 

  88. Buzdar A. The ATAC (‘arimidex’, tamoxifen, alone or in combination) trial in postmenopausal women with early breast cancer — updated efficacy results based on a median follow-up of 47 months. Breast Cancer Res Treat. 77, 295. 2003. Ref Type: abstr

    CAS  Google Scholar 

  89. Goss PE, Ingle JN, Pater JL et al (2008) Late extended adjuvant treatment with letrozole improves outcome in women with early stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 26(12):1948–55

    CAS  PubMed  Google Scholar 

  90. Miller WH Jr (1998) The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer. 83(8):1471–82

    CAS  PubMed  Google Scholar 

  91. Veronesi U, De Palo G, Marubini E et al (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 91(21):1847–56

    CAS  PubMed  Google Scholar 

  92. Anzano MA, Byers SW, Smith JM et al (1994) Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 54(17):4614–7

    CAS  PubMed  Google Scholar 

  93. Van WJ, Van NG, Coene MC et al (1992) Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther. 261(2):773–9

    Google Scholar 

  94. Van Wauwe JP, Coene MC, Goossens J, Cools W, Monbaliu J (1990) Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans retinoic acid in rats. J Pharmacol Exp Ther. 252(1):365–9

    PubMed  Google Scholar 

  95. Bruynseels J, De CR, Van RP et al (1990) R 75251, a new inhibitor of steroid biosynthesis. Prostate. 16(4):345–57

    CAS  PubMed  Google Scholar 

  96. Van WJ, Coene MC, Cools W et al (1994) Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid. Biochem Pharmacol. 47(4):737–41

    Google Scholar 

  97. Goss PE, Oza A, Goel R et al (2000) Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor-positive postmenopausal metastatic breast cancer. Breast Cancer Res Treat. 59(1):55–68

    CAS  PubMed  Google Scholar 

  98. Goss PE, Strasser K, Marques R et al (2000) Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer. Breast Cancer Res Treat. 64(2):177–88

    CAS  PubMed  Google Scholar 

  99. Ingram D, Sanders K, Kolybaba M, Lopez D (1997) Case-control study of phyto-oestrogens and breast cancer. Lancet. 350(9083):990–4

    CAS  PubMed  Google Scholar 

  100. Serraino M, Thompson LU (1992) The effect of flaxseed supplementation on the initiation and promotional stages of mammary tumorigenesis. Nutr Cancer. 17(2):153–9

    CAS  PubMed  Google Scholar 

  101. Wang C, Makela T, Hase T, Adlercreutz H, Kurzer MS (1994) Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol. 50(3–4):205–12

    CAS  PubMed  Google Scholar 

  102. Haggans CJ, Hutchins AM, Olson BA, Thomas W, Martini MC, Slavin JL (1999) Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. Nutr Cancer. 33(2):188–95

    CAS  PubMed  Google Scholar 

  103. Serraino M, Thompson LU (1991) The effect of flaxseed supplementation on early risk markers for mammary carcinogenesis. Cancer Lett. 60(2):135–42

    CAS  PubMed  Google Scholar 

  104. Lamartiniere CA, Moore JB, Brown NM, Thompson R, Hardin MJ, Barnes S (1995) Genistein suppresses mammary cancer in rats. Carcinogenesis. 16(11):2833–40

    CAS  PubMed  Google Scholar 

  105. Hawrylewicz EJ, Zapata JJ, Blair WH (1995) Soy and experimental cancer: animal studies. J Nutr. 125(3 Suppl):698S–708S

    CAS  PubMed  Google Scholar 

  106. Barnes S (1995) Effect of genistein on in vitro and in vivo models of cancer. J Nutr. 125(3 Suppl):777S–83S

    CAS  PubMed  Google Scholar 

  107. Lu LJ, Anderson KE, Grady JJ, Nagamani M (1996) Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Cancer Epidemiol Biomark Prev. 5(1):63–70

    CAS  Google Scholar 

  108. Stoll BA (1997) Eating to beat breast cancer: potential role for soy supplements. Ann Oncol. 8(3):223–5

    CAS  PubMed  Google Scholar 

  109. Baum M, Ziv Y, Colletta A (1991) Prospects for the chemoprevention of breast cancer. Br Med Bull. 47(2):493–503

    CAS  PubMed  Google Scholar 

  110. Knekt P (1991) Role of vitamin E in the prophylaxis of cancer. Ann Med. 23(1):3–12

    CAS  PubMed  Google Scholar 

  111. Charpentier A, Groves S, Simmons-Menchaca M et al (1993) RRR-alpha-tocopheryl succinate inhibits proliferation and enhances secretion of transforming growth factor-beta (TGF-beta) by human breast cancer cells. Nutr Cancer. 19(3):225–39

    CAS  PubMed  Google Scholar 

  112. Kimmick GG, Bell RA, Bostick RM (1997) Vitamin E and breast cancer: a review. Nutr Cancer. 27(2):109–17

    CAS  PubMed  Google Scholar 

  113. Lippman SM, Benner SE, Hong WK (1994) Cancer chemoprevention. J Clin Oncol. 12(4):851–73

    CAS  PubMed  Google Scholar 

  114. Goodman GE (1992) The clinical evaluation of cancer chemoprevention agents: defining and contrasting phase I, II, and III objectives. Cancer Res. 52(9 Suppl):2752s–7s

    CAS  PubMed  Google Scholar 

  115. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong WK (1990) Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst. 82(7):555–60

    CAS  PubMed  Google Scholar 

  116. Schatzkin A, Freedman LS, Schiffman MH, Dawsey SM (1990) Validation of intermediate end points in cancer research. J Natl Cancer Inst. 82(22):1746–52

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wilhelminen Hospital, Vienna, Austria

    Kathrin Strasser-Weippl

  2. Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, 02115, USA

    Paul E. Goss

Authors
  1. Kathrin Strasser-Weippl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul E. Goss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul E. Goss .

Editor information

Editors and Affiliations

  1. Breast Care Center National Naval Medical Center, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814, USA

    Ismail Jatoi (Head) (Head)

  2. Women’s Hospital, University of Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany

    Manfred Kaufmann (Breast Unit Director) (Breast Unit Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Strasser-Weippl, K., Goss, P.E. (2010). Chemoprevention of Breast Cancer. In: Jatoi, I., Kaufmann, M. (eds) Management of Breast Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69743-5_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-69743-5_30

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-69742-8

  • Online ISBN: 978-3-540-69743-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation